Nearly a fifth of patients with cancer being treated with mitogen-activated protein kinase (MEK) inhibitors in clinical trials developed an ocular adverse event, according to a research letter ...

Pasithea Therapeutics announced promising preclinical data for PAS-004, a next-generation MEK inhibitor, which shows superior effectiveness in inhibiting the ETS2 pathway associated with ...

CNW/ - Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib), an oral, selective MEK inhibitor, has been approved in ...

Long-Term Follow-Up of Real-World Adjuvant Anti–PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma In this phase II, open-label study, patients with recurrent, ...

MEK inhibitors are frequently associated with cutaneous adverse events in pediatric patients, and binimetinib was associated with more severe reactions than selumetinib in a retrospective study, which ...

Rare Disease's Koselugo (selumetinib), an oral, selective MEK inhibitor, has been approved in Canada for the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, ...

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma The following represents disclosure information ...

Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor mirdametinib, a large multicenter study of the rare condition showed. Overall, 53 ...

For patients with advanced melanoma without BRAF mutation who no longer respond to immune checkpoint inhibitors, treatment ...